Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal of a phase 2 trial.The shares have struggled with overhead pressure at $12 for the past several weeks, after spending all year downtrending to a Nov. 11, three-year low of $7.49. So far in 2026, BHVN has shed over 70%.The stock looks overdue for a round of bear notes, as 11 of the 18 analysts in question still spor ...